Evercore ISI Issues Positive Forecast for Intuitive Surgical (NASDAQ:ISRG) Stock Price

Intuitive Surgical (NASDAQ:ISRG) had its target price lifted by stock analysts at Evercore ISI from $490.00 to $530.00 in a report released on Monday. Evercore ISI’s price target indicates a potential downside of 7.69% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Leerink Partners upped their price target on Intuitive Surgical from $490.00 to $548.00 in a report on Monday. Truist Financial lifted their price target on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Citigroup raised their target price on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a report on Friday, January 24th. Mizuho increased their price target on shares of Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Finally, BTIG Research lifted their price objective on Intuitive Surgical from $535.00 to $561.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $574.14 on Monday. Intuitive Surgical has a one year low of $364.17 and a one year high of $616.00. The company’s fifty day moving average is $548.00 and its two-hundred day moving average is $506.12. The firm has a market capitalization of $204.50 billion, a P/E ratio of 92.31, a PEG ratio of 5.19 and a beta of 1.39.

Insider Transactions at Intuitive Surgical

In other news, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at approximately $6,955,015. This trade represents a 27.41 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jamie Samath sold 22,903 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the sale, the insider now owns 8,757 shares of the company’s stock, valued at approximately $4,597,425. This represents a 72.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,749 shares of company stock worth $15,303,875 in the last three months. 0.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Intuitive Surgical

Hedge funds have recently modified their holdings of the stock. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical in the fourth quarter valued at approximately $26,000. Godsey & Gibb Inc. grew its holdings in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares in the last quarter. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical during the 3rd quarter worth $33,000. Decker Retirement Planning Inc. purchased a new position in Intuitive Surgical in the 4th quarter valued at about $36,000. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Intuitive Surgical during the third quarter worth about $38,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.